Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

NCT00966251 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped because of slow accrual

Conditions

Primary Hepatocellular Carcinoma

Interventions

DRUG: CT-011

Sponsor

CureTech Ltd

Collaborators

[object Object]